Study selection
• All randomized controlled clinical trials assessing baclofen versus placebo or other comparators • For at least four weeks' treatment duration • In alcohol-dependent patients according to the DSM-IV or ICD-10 classification
Outcomes
• Primary outcome: percentage of patients who had not consumed alcohol at the end of the treatment period • Secondary outcomes:
-the cumulative abstinence days -the indexes of craving, as well as the variation of craving between the inclusion of patients and the end of the study measured by Obsessive Compulsive Drinking Scale (OCDS) and Penn Alcohol Drinking Scale (PACS)
Statistical analysis
Pooling the logarithm of the relative risks for binary outcomes or mean differences for quantitative scale weighted by the inverse of the variance of each trial. Random-effect model in case of unexplained heterogeneity with a fixed-effect model. (P2T) • Alcohol consumption: approximately responsible to 4% of the global burden of disease.
EFFICACY OF BACLOFEN ON ABSTINENCE AND CRAVING IN ALCOHOL-DEPENDANT PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
• Craving: a significant component of alcohol dependence or psychological dependence.
• To date, the efficacy of available drugs remains controversial and does not ensure complete abstinence in patients.
• Baclofen is a stereo-selective gamma-aminobutyric acid B (the GABAB) receptor agonist that may exert an inhibitory action on the dopamine neurons. It is approved in indication to control spasticity. Preclinical experiments have demonstrated its efficacy in suppressing alcohol withdrawal signs and voluntary intake.
• Several randomized controlled clinical trials have evaluated the efficacy of baclofen in alcohol-dependent patients on abstinence and craving compared to placebo but not synthesis is available to give a global estimate of its efficacy.
•Low dosages of baclofen is associated with a 179% increase of abstinent patients at the end of the treatment period compared to the patients treated by placebo (Figure 1 ).
•The same trend is found for the cumulative abstinent days and craving measured by OCDS despite the lack of significant result (Figures 2 and 3) . The unexplained heterogeneity observed on these secondary outcomes may be due to the difference in treatment duration, the average alcohol consumption of patients before inclusion or the average period of addiction before inclusion.
•This meta-analysis shows an increase of abstinence and a partially decrease of craving associated with baclofen that is in accordance with its expected pharmacological effect.
•The main limitation of our meta-analysis stems from the low number of studies included in the meta-analysis and the lack of consensus on outcomes used.
•Our meta-analysis brings support towards an efficacy of low dosages of baclofen on the maintenance of abstinence in alcohol-dependent patients, but the robustness of the result is very weak. Results on craving needs to be confirmed by furthers studies. 
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